Skip to main
  1. Stocks
  2. DexCom
  3. Forecast
DXCM

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 57%
Buy 33%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

DexCom is positioned for a positive fundamental trajectory because its 3Q results beat expectations, with Adjusted EPS of $0.72 on revenue of $1.345 billion and Adjusted EBITDA of $435 million, while management also narrowed 2026 revenue guidance to $5.200-5.250 billion and expects roughly 64% non-GAAP gross margins and 24% operating margins. The company’s G7 15-Day rollout, lower-cost manufacturing upgrades, and nearly 50% conversion target by year-end support margin expansion, and the newly authorized $1 billion buyback underscores confidence in strong free cash flow generation. Longer term, DexCom’s bull case is reinforced by CONNECT trial data showing a −1.6% A1c reduction versus −0.7% in control, ~97% adherence, and broad reimbursement upside in the large T2NIT market, where CMS coverage could materially expand access.

Bears say

DexCom is facing a deteriorating fundamental profile because its CGM franchise is exposed to rapid product obsolescence, stronger competitor innovation, and the risk that delayed new launches or weaker market adoption could erode revenue and operating results. The company also carries meaningful execution and regulatory risk, including possible Ireland factory ramp issues, post-market safety concerns, recalls, product liability claims, and patent litigation that could interrupt sales, raise costs, or damage its competitive moat. At the same time, global reimbursement pressure from payors and governments, plus inflation-driven higher operating expenses and interest costs, threatens margins and profitability even as the company requires heavy investment to keep pace with a premium-valued diabetes device sector.

DexCom (DXCM) has been analyzed by 21 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 33% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

DexCom (DXCM) Analyst Forecast & Price Prediction

Get the latest DexCom (DXCM) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in DexCom (DXCM)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 21 analysts, DexCom (DXCM) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $92.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $92.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


DexCom (DXCM) Analyst Forecast & Price Prediction

Get the latest DexCom (DXCM) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in DexCom (DXCM)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover DXCM stock data and trends